{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:28:23Z","timestamp":1771874903578,"version":"3.50.1"},"reference-count":35,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Alopecia areata is a prevalent autoimmune condition causing non-scarring alopecia, with significant impacts on quality of life. However, the long-term effects on major life-changing decisions remain understudied. A cross-sectional study was performed including patients with alopecia areata who attended the Dermatology Department of the Virgen de las Nieves University Hospital. Patients were asked to complete questionnaires to assess the impact of alopecia areata on major life-changing decisions and quality of life. A total of 70 patients were included: 71% were female and 29% were male. The mean age was 38.70 (SD 14.32). The most affected major life-changing decisions were couple relationships and dressing; followed by job performance, social relationships, lifestyle changes, and sports practice. Female gender, higher therapeutic burden, or Dermatology Life Quality Index scores, and lower World Health Organization Five Well Being Index rating were significantly associated with greater major life-changing decisions impairment (p\u2009&lt;\u20090.05). Disease severity and duration did not correlate with increased impact in most major life-changing decisions (p\u2009&gt;\u20090.10). In conclusion, there are some major life-changing decisions that appear to be significantly affected in patients with alopecia areata. The identification of factors associated such us female gender, therapeutic burden, or alterations in mental well-being is crucial to explore and limit the long-term negative effects of the disease.<\/jats:p>","DOI":"10.2340\/actadv.v105.43039","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:38:41Z","timestamp":1757500721000},"page":"adv43039","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Alopecia Areata on Major Life-changing Decisions: Prevalence and Associated Factors"],"prefix":"10.2340","volume":"105","author":[{"given":"Daniel","family":"Mu\u00f1oz-Barba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Soto-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Haselgruber-de Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"S\u00e1nchez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"126085","doi-asserted-by":"crossref","unstructured":"Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg 2023; 27: 241\u2013259.","DOI":"10.1177\/12034754231168839"},{"key":"126086","doi-asserted-by":"crossref","unstructured":"Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia areata: burden of disease, approach to treatment, and current unmet needs. Clin Cosmet Investig Dermatol 2023; 16: 803\u2013820.","DOI":"10.2147\/CCID.S376096"},{"key":"126087","doi-asserted-by":"crossref","unstructured":"Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol 2023; 14: 1152513.","DOI":"10.3389\/fimmu.2023.1152513"},{"key":"126088","doi-asserted-by":"crossref","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Blume-Peytavi U, Farrant P, Reygagne P, Johansson E, Reed C, et al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries. Dermatol Ther 2023; 13: 3121\u20133135.","DOI":"10.1007\/s13555-023-01057-0"},{"key":"126089","doi-asserted-by":"crossref","unstructured":"Lauron S, Plasse C, Vaysset M, D\u2019Incan M, Rondepierre F, Jalenques I. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol 2023; 159: 281\u2013288.","DOI":"10.1001\/jamadermatol.2022.6085"},{"key":"126090","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-D\u00edaz M, D\u00edaz-Calvillo P, Ure\u00f1a-Paniego CA, Molina-Leyva A, Arias-Santiago S. Quality of life and mood status disturbances in cohabitants of patients with alopecia areata: a cross-sectional study in a Spanish population. Int J Environ Res Public Health 2022; 19: 16323.","DOI":"10.3390\/ijerph192316323"},{"key":"126091","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-D\u00edaz M, Montero-V\u00edlchez T, Cuenca-Barrales C, Molina-Leyva A, Arias-Santiago S. Prevalence and implications of type D personality in patients with alopecia areata: a marker of quality-of-life impairment and mood status disturbances, a comparative study. J Eur Acad Dermatol Venereol 2023; 37: 1064\u20131070.","DOI":"10.1111\/jdv.18733"},{"key":"126092","doi-asserted-by":"crossref","unstructured":"Mayer KU. New directions in life course research. Annu Rev Sociol 2009; 35: 413\u2013433.","DOI":"10.1146\/annurev.soc.34.040507.134619"},{"key":"126093","doi-asserted-by":"crossref","unstructured":"Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annu Rev Public Health 2005; 26: 1\u201335.","DOI":"10.1146\/annurev.publhealth.26.021304.144505"},{"key":"126094","doi-asserted-by":"crossref","unstructured":"Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002; 31: 285\u2013293.","DOI":"10.1093\/ije\/31.2.285"},{"key":"126095","doi-asserted-by":"crossref","unstructured":"Kimball A, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989\u20131004.","DOI":"10.1111\/j.1468-3083.2010.03705.x"},{"key":"126096","doi-asserted-by":"crossref","unstructured":"Bhatti Z, Salek M, Finlay A. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol 2011; 25: 245\u2013246.","DOI":"10.1111\/j.1468-3083.2010.03930.x"},{"key":"126097","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger C, Schallreuter KU. Cumulative life course impairment in vitiligo. Curr Probl Dermatol 2013; 44: 102\u2013117.","DOI":"10.1159\/000350010"},{"key":"126098","doi-asserted-by":"crossref","unstructured":"Augustin M. Cumulative life course impairment in chronic wounds. Curr Probl Dermatol 2013; 44: 125\u2013129.","DOI":"10.1159\/000350789"},{"key":"126099","doi-asserted-by":"crossref","unstructured":"Fine JD. Cumulative life course impairment by epidermolysis bullosa. Curr Probl Dermatol 2013; 44: 91\u2013101.","DOI":"10.1159\/000350009"},{"key":"126100","doi-asserted-by":"crossref","unstructured":"Piaserico S. Cumulative life course impairment in melanoma and nonmelanoma skin cancer. Curr Probl Dermatol 2013; 44: 118\u2013124.","DOI":"10.1159\/000350055"},{"key":"126101","doi-asserted-by":"crossref","unstructured":"Burns LJ, Mesinkovska N, Kranz D, Ellison A, Senna MM. Cumulative life course impairment of alopecia areata. Int J Trichology 2020; 12: 197\u2013204.","DOI":"10.4103\/ijt.ijt_99_20"},{"key":"126102","doi-asserted-by":"crossref","unstructured":"Jebb AT, Ng V, Tay L. A review of key Likert scale development advances: 1995\u20132019. Front Psycho 2021; 12: 637547.","DOI":"10.3389\/fpsyg.2021.637547"},{"key":"126103","doi-asserted-by":"crossref","unstructured":"Bhatti ZU, Salek SS, Bolton CE, George L, Halcox JP, Jones S, et al. The development and validation of the major life changing decision profile (MLCDP). Health Qual Life Outcomes 2013; 11: 78.","DOI":"10.1186\/1477-7525-11-78"},{"key":"126104","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210\u2013216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"126105","unstructured":"de Tiedra AG, Mercadal J, Bad\u00eda X, Mascar\u00f3 JM, Herdman M, Lozano R. Adaptaci\u00f3n transcultural al espa\u00f1ol del cuestionario Dermatology Life Quality Index (DLQI): El \u00cdndice de Calidad de Vida en Dermatolog\u00eda. Actas Dermo-Sifiliogr\u00e1ficas 1998; 89: 692\u2013700."},{"key":"126106","doi-asserted-by":"crossref","unstructured":"Carrozzino D, Christensen KS, Patierno C, Wo\u017aniewicz A, M\u00f8ller SB, Arendt ITP, et al. Cross-cultural validity of the WHO-5 Well-Being Index and Euthymia Scale: a clinimetric analysis. J Affect Disord 2022; 311: 276\u2013283.","DOI":"10.1016\/j.jad.2022.05.111"},{"key":"126107","unstructured":"Psykiatric Center North Zealand. WHO\u20115 Questionnaires [Internet]. Hiller\u00f8d (Denmark): Region Hovedstadens Psykiatri. Available from: https:\/\/www.psykiatri-regionh.dk\/who-5\/who-5-questionnaires\/Pages\/default.aspx"},{"key":"126108","doi-asserted-by":"crossref","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361\u2013370.","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"126109","doi-asserted-by":"crossref","unstructured":"Vilela-Estrada AL, Villarreal-Zegarra D, Copez-Lonzoy A, Esenarro-Valencia L, S\u00e1nchez-Ram\u00edrez JC, Lamas-Delgado F, et al. Psychometric properties of the Spanish version of the hospital anxiety and depression scale in cancer patients. Front Psychol. 2024; 15: 1497946.","DOI":"10.3389\/fpsyg.2024.1497946"},{"key":"126110","doi-asserted-by":"crossref","unstructured":"Olsen EA, Canfield D. SALT II: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol 2016; 75: 1268\u20131270.","DOI":"10.1016\/j.jaad.2016.08.042"},{"key":"126111","doi-asserted-by":"crossref","unstructured":"Haselgruber S, Mu\u00f1oz-Barba D, Leon-P\u00e9rez FJ, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Therapeutic burden in hidradenitis suppurativa: a cross-sectional study of 557 patients. Int J Dermatol 2025; 64: 539\u2013545.","DOI":"10.1111\/ijd.17517"},{"key":"126112","doi-asserted-by":"crossref","unstructured":"Li SJ, Huang KP, Joyce C, Mostaghimi A. The impact of alopecia areata on sexual quality of life. Int J Trichology 2018; 10: 271\u2013274.","DOI":"10.4103\/ijt.ijt_93_18"},{"key":"126113","doi-asserted-by":"crossref","unstructured":"Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol 2001; 19(2): 161\u2013166.","DOI":"10.1016\/S0738-081X(00)00127-9"},{"key":"126114","doi-asserted-by":"crossref","unstructured":"Kacar SD, Soyucok E, Bagcioglu E, Ozuguz P, Coskun KS, As\u0131k AH, et al. The perceived stigma in patients with alopecia and mental disorder: a comparative study. Int J Trichology 2016; 8: 135\u2013140.","DOI":"10.4103\/0974-7753.189005"},{"key":"126115","doi-asserted-by":"crossref","unstructured":"Macbeth AE, Holmes S, Harries M, Chiu WS, Tziotzios C, de Lusignan S, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol 2022; 187: 73\u201381.","DOI":"10.1111\/bjd.21055"},{"key":"126116","doi-asserted-by":"crossref","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient-Rep Outcomes 2020; 4: 76.","DOI":"10.1186\/s41687-020-00240-7"},{"key":"126117","doi-asserted-by":"crossref","unstructured":"Senna M, Ko J, Glashofer M, Walker C, Ball S, Edson-Heredia E, et al. Predictors of QOL in patients with alopecia areata. J Invest Dermatol 2022; 142: 2646\u20132650.e3.","DOI":"10.1016\/j.jid.2022.02.019"},{"key":"126118","doi-asserted-by":"crossref","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc 2020; 20: S62\u2013S68.","DOI":"10.1016\/j.jisp.2020.05.007"},{"key":"126119","doi-asserted-by":"crossref","unstructured":"von St\u00fclpnagel CC, Augustin M, D\u00fcpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases: a systematic review. J Eur Acad Dermatol Venereol 2021; 35: 2166\u20132184.","DOI":"10.1111\/jdv.17348"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43039\/51375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43039\/51375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:38:49Z","timestamp":1757500729000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43039","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}